You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
COMPANY PROFILE
Beijing Avistone Biotechnology Co., Ltd.
Avistone is a commercial-stage innovative biopharmaceutical company, and is committed to delivering high-quality innovative drugs to oncology patients worldwide, enabling them to achieve a better quality of life.
For a decade, Avistone has been dedicated to first-in-class and best-in-class drugs, and has established a strong pipeline comprising multiple novel therapies, with several candidates in advanced global clinical development.
OUR CULTURE
-
Company Vision
To become a trustworthy biopharmaceutical company
Committed to human health through continuous innovation
Vision
-
Core Values
Integrity
Accountability
Pragmatism
Cooperation
Values
HISTORY
-
2025
· Vebreltinib's MET amplification related NSCLC indication was approved in China
· Andamertinib's NDA proposal for NSCLC related indication was accepted by CDE and granted as Priority Review in China
-
2024
· Vebreltinib's ZM fusion gene related GBM indication was approved in China
· The results of the key registration study of Vebreltinib in treating NSCLC were published in the international top medical journal Journal of Clinical Oncology (JCO)
· Two approved indications of Vebreltinib were included in the China's 2024 National Reimbursement Drug List
· Completed over $35 million Series B+ funding from Beijing Medical and Health Care Industry Investment Fund (Limited Partnership) and Beijing Daxing District Industrial Development Fund
-
2023
· Vebreltinib's MET exon 14 skipping NSCLC related indication was approved in China
· Completed over $140 million in Series B funding from CS Capital, IDG Capital, Yanchuang Capital, Bain Capital and Cathy Capital
-
2022
· NDA proposal for Vebreltinib was accepted by CDE and granted as Priority Review
-
2021
· Vebreltinib was granted with breakthrough therapy by CDE
· Completed over US$200 million in Series A funding from Vivo Capital, Bain Capital, and Primavera Capital
-
2020
· Obtained IND approval for PLB1004 in China, and the clinical trials were initiated
-
2018
• Beijing Avistone Biotechnology Co., Ltd. was established
• The mechanism of action and phase I trial results of Vebreltinib in glioma were published in the international top medical journal Cell
• The precision treatment of the indication of Vebreltinib for gliomas was selected as one of the Top Ten Advances in Life Sciences in China in 2018 by the China Association for Science and Technology
-
2016
· Vebreltinib clinical research was selected for China's National 13th Five-Year Plan Major New Drug Innovation Program
-
2015
· Obtained IND approval for Vebreltinib, and the clinical trials were initiated
-
2012
• Beijing Pearl Biotechnology Co., Ltd. was established
